Although high-density lipoprotein cholesterol has been deemed the “good cholesterol,” this label may be misleading and outdated given that there is little evidence to support a causal relationship with CVD risk reduction.
This large-scale analysis found a consistent, robust reduction in LDL-C with alirocumab across a wide range of ages regardless of hypertension or smoking status.
Maternal obesity and gestational diabetes may have important effects on early child body composition, but likely do not directly affect left ventricular mass in offspring.
Results from a phase 3 trial evaluating the efficacy of evinacumab in the treatment of patients with HoFH showed that the investigational ANGPTL3 antibody reduced LDL-C by 49%.
Increased variations of body mass index and high-density lipoprotein cholesterol during childhood are independent risk factors for the development of diabetes.
Lexicon Pharmaceuticals announced new data from the phase 3 inTandem1 and inTandem2 studies of sotagliflozin in adult patients with type 1 diabetes.
Blood pressure, waist circumference, fasting lipid profile, and blood glucose should be measured regularly to identify ASCVD and T2DM.
The Endocrine Society published a clinical practice guideline cosponsored by the American Diabetes Association and the European Society of Endocrinology regarding the primary prevention of ASCVD and T2D.
Higher HbA1c levels in the year prior to ablation were linked to an increased risk for post-ablation AF recurrence in patients with diabetes.
Glucocorticoid replacement therapy is associated with an increase in serum levels of adiponectin and high-density lipoprotein cholesterol.
A study analyzes the real-world effects of access to PCSK9imedications on ASCVD events.
Want to read more?
Please login or register first to view this content.
Next post in Dyslipidemia